Breakthrough in Multiple Myeloma Treatment with Single-Dose CAR-T Therapy
A study shows that a single infusion of CAR-T therapy cilta-cel can lead to at least five years of remission in about one-third of patients with relapsed or refractory multiple myeloma, suggesting potential curative outcomes for some patients.